Vol. 2 No. 9 (2022)
Reimbursement Reviews

Selpercatinib (Retevmo)

Published September 29, 2022

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses selpercatinib (Retevmo) 40 and 80 mg capsules, oral.
  • Indication: Adult patients with rearranged during transfection (RET) fusion–positive differentiated thyroid carcinoma with advanced or metastatic disease (not amenable to surgery or radioactive iodine therapy) following prior treatment with sorafenib and/or lenvatinib.